**Abstract**

In late 2014, the CINP published the report of a summit convened to identify various ways to move forward in drug development for CNS disorders (Andersen et al., Nature Reviews Drug Discovery, 13:871). One component of this report included a recommendation for consideration of the Research Domain Criteria (RDoC) developed by the US National Institute of Mental Health. The RDoC was developed as a research framework for studying mental disorders in terms of deviations from normative behaviors and cognitive processes, and perturbations in the neural systems that implement these processes. The approach was developed explicitly to address the increasing realization that mental disorders (and potentially many neurological disorders as well) represent broad, heterogeneous syndromes rather than specific disease entities -- a problem that may well represent a substantial component of the reasons for recent problems in drug discovery for CNS disorders. The idea is that studying more specific functions, which often relate to specific symptom clusters such as cognition or disrupted reward processing, may eventually provide more homogeneous patient groupings and facilitate successful drug discovery efforts.

In this address, I will first describe the rationale for the RDoC project, and outline its two major components as a theory of psychopathology and as a specific set of criteria for reviewing grant applications. This discussion will include a brief discussion about efforts toward biomarker development, and how biomarkers are viewed in terms of the integrative design of the RDoC research framework. These remarks will provide a context to clarify some of the misunderstandings that have arisen about the project. Finally, the talk will conclude with a discussion of RDoC as it relates to the current NIMH approach to clinical trials, and how the trials portfolio fits into the overall Institute priorities for research on mental disorders.
